Welcome to BioMarin's Online Press Room.
We've brought together a variety of information in one location
to better assist you in your efforts to research and develop
news articles. Should you require additional information, please
call or e-mail us any time.
BioMarin Announces Two Oral and 19 Poster Presentations at the Society for the Study of Inborn Errors of Metabolism 2015 Annual Meeting... MORE >Medivation to Expand Global Oncology Franchise With the Acquisition of All Worldwide Rights to Talazoparib (BMN 673), a Potent PARP Inhibitor, From BioMarin... MORE >BioMarin Receives Rare Pediatric Disease Designation From FDA for Drisapersen for the Potential Treatment of Duchenne Muscular Dystrophy... MORE >